GLP-1GIPGCG
Retatrutide
Triple-Agonist · GLP-1/GIP/GCG
5.0(4)
From
$138.86
Research peptides studied in preclinical and clinical work on appetite regulation, glucose homeostasis, and fat metabolism. The category groups incretin receptor agonists such as Retatrutide (GLP-1/GIP/GCG) and Tirzepatide (GLP-1/GIP), which engage several hormone receptors along the gastrointestinal axis, alongside metabolic and mitochondrial peptides such as MOTS-c, AOD-9604, 5-Amino-1MQ, and the cofactor NAD+. Every peptide is supplied at 99% HPLC purity strictly as Research Use Only.
Research peptides spanning appetite, glucose homeostasis and fat metabolism: from the triple agonist Retatrutide and the dual agonist Tirzepatide to mitochondrial peptides such as MOTS-c and the cofactor NAD+. Every compound is supplied at 99% HPLC purity strictly as Research Use Only.
Metabolic research protocols often pair incretin agonists with peptides targeting lipolysis, the growth-hormone axis, or mitochondrial metabolism, for example Tirzepatide with Tesamorelin, Retatrutide with AOD-9604, or MOTS-c alongside a GLP-1 agonist.
Incretin receptor agonists are peptides that mimic the action of endogenous gut hormones such as GLP-1 (Glucagon-like Peptide 1) and GIP (Glucose-dependent Insulinotropic Polypeptide). In metabolic research they serve as tools to probe the mechanisms of insulin secretion, gastric emptying, satiety signaling, and energy balance. By selectively activating one or several incretin receptors, investigators can dissect their individual contributions to glucose regulation and fat metabolism. Triple agonists such as Retatrutide add a Glucagon receptor arm, allowing researchers to study combined effects on appetite, insulin response, and energy expenditure within a single molecule.
The Weight Management category groups research peptides used in studies on appetite regulation, glucose homeostasis, and fat metabolism. At its core are incretin receptor agonists that engage one, two, or three hormone receptors along the gastrointestinal axis depending on the molecule. Retatrutide is a triple agonist at the GLP-1, GIP, and Glucagon (GCG) receptors with a plasma half-life of roughly 6 days (Jastreboff et al., NEJM 2023, TRIUMPH program), studied in models of obesity and metabolic dysfunction. Tirzepatide is a dual agonist at GLP-1 and GIP with a half-life of roughly 5 days (Eli Lilly, SURPASS-1) and a substantially broader clinical dataset across diabetes and obesity research. Beyond the incretins, the category includes metabolic and mitochondrial peptides: MOTS-c, a mitochondrially encoded peptide with a half-life of roughly 12 hours (Lee et al., Cell Metabolism 2015), the growth-hormone fragment AOD-9604, and 5-Amino-1MQ, a small-molecule NNMT inhibitor, plus the cofactor NAD+. This breadth lets researchers contrast appetite- and glucose-driven mechanisms against lipolytic and mitochondrial pathways.
The incretin agonists in this category differ mainly in the number of receptors they engage at once. Each additional receptor arm extends the pharmacological profile, and with it the metabolic endpoints researchers can probe in preclinical models. The overview below sorts the classes using the peptides actually carried in this category:
Beyond the incretin axis, the category groups peptides and cofactors that address metabolism through entirely different mechanisms and therefore serve as complementary comparison arms. MOTS-c is a mitochondrially encoded peptide linked in research to the AMPK pathway, insulin sensitivity, and skeletal-muscle energetics (Lee et al., Cell Metabolism 2015); its half-life is roughly 12 hours. NAD+ is a redox cofactor studied as a systemic substrate in work on energy metabolism, mitochondrial function, and longevity; its plasma half-life sits in the range of roughly 1 to 2 hours. 5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT) and is characterized in preclinical models in connection with adipocyte metabolism and the cellular NAD+ pool. Unlike the incretins, which signal through hormone receptors of the gut-brain axis, these tools act directly on intracellular energy metabolism. This lets researchers cleanly separate appetite- and glucose-driven pathways from mitochondrial and lipolytic mechanisms.
The peptides in this category are characterized against clearly defined endpoints in in-vitro and preclinical models; every quantity referenced below applies to study design only and not to any human application. Satiety and appetite models are central, measuring food intake, gastric emptying, and central signaling pathways of energy balance. Glycemic control is quantified through glucose-dependent insulin secretion, insulin sensitivity, and glucose tolerance, often comparing the mono, dual and triple agonists. For the lipolytic component, fat oxidation and lipolysis in the adipocyte serve as readouts, particularly for AOD-9604 and HGH Fragment 176-191, which model these effects without meaningful IGF-1 elevation. At the body-composition level, fat mass, visceral adipose tissue, and lean mass are recorded as readouts in animal models. MOTS-c and NAD+ extend these endpoints with mitochondrial markers such as AMPK activation and cellular energy status. In this way, appetite-, glucose-, and fat-metabolism-driven mechanisms can be studied comparatively within a single category.
Every batch is tested by high-performance liquid chromatography (HPLC) for 99% purity and confirmed in its molecular identity by mass spectrometry. Certificates of Analysis (CoA) are available on request and mapped to the specific peptide; each product page lists the molecular weight, amino acid sequence, and, where published, the receptor affinity. The entire category is labeled strictly as Research Use Only (RUO) and is not intended for human or veterinary application. Lyophilized peptides are stable at minus 20 °C for 24 months and should be kept dry and protected from light until use. For experimental work they are typically reconstituted with bacteriostatic water; the resulting solution is usable at 2 to 8 °C for 28 days. Adding the diluent slowly down the wall of the vial and rotating gently rather than shaking prevents foaming and shear-related degradation. Aliquoting into smaller portions reduces repeated freeze-thaw cycles. Detailed guidance on target concentrations, volumes, and half-life is available in the research guides for Retatrutide and Tirzepatide.